Insiders Buying These 4 Penny Stocks
The Nasdaq Composite gained around 60 points on Wednesday. Investors, meanwhile, focused on some notable insider trades.
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Insiders Buy Over $1.3M Of 4 Penny Stocks
The Dow Jones tumbled more than 150 points on Monday. Investors, meanwhile, focused on some notable insider trades.
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's session, 454 stocks hit new 52-week lows.
Lineage Cell Therapeutics Q4 EPS $(0.17) Misses $(0.05) Estimate, Sales $1.20M Beat $840.00K Estimate
Lineage Cell Therapeutics (AMEX:LCTX) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.05) by 240 percent. This is a 1800 percent decrease over earnings of $0.01 per share
Lineage Cell Therapeutics’s Earnings: A Preview
Lineage Cell Therapeutics (AMEX:LCTX) is set to give its latest quarterly earnings report on Thursday, 2022-03-10. Here's what investors need to know before the announcement.
Analysts estimate that Lineage Cell Therapeutics will report an earnings per share (EPS) of $-0.05.
The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg
Biotech stocks reversed course in the week ending March 4, as the Ukrainian crisis weighed down on the broader market as well as the sector. The iShares Biotechnology ETF (NASDAQ: IBB) retreated in four out of five sessions of the week.
65 Biggest Movers From Yesterday
Gainers
Society Pass Incorporated (NASDAQ: SOPA) shares climbed 240.2% to close at $11.26 on Monday after the company reported addition to the Russell 2000 Index.
Lineage Establishes Exclusive Worldwide Collaboration With Genentech For The Development And Commercialization Of OpRegen RPE Cell Therapy For The Treatment Of Ocular Disorders; Genentech Will Pay Lineage $50M Upfront
Genentech Will Pay Lineage $50 Million Upfront
Eligible to Receive a Total of $670 Million in Upfront and Milestone Payments
Conference Call to Discuss Collaboration Planned for 8 a.m.